SEC Form 4 · accession 0001209191-18-057721
Kura Oncology, Inc. · KURA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mary T Szela
Director
Period of report
Nov 6, 2018
Accepted (ET)
Nov 8, 2018 · 2:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001422143
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF1 | $11.55 | Nov 6, 2018 | A | 30,000 | A | — | Nov 5, 2028 | Common Stock | 30,000 | 30,000 | D |
| Option to purchase common stockF2 | $11.55 | Nov 6, 2018 | A | 7,583 | A | — | Nov 5, 2028 | Common Stock | 7,583 | 7,583 | D |
Explanation of responses
- F1This option vests in three equal annual installments commencing on the one year anniversary of the date of grant.
- F2This option vests in full on the one year anniversary of the date of grant.